Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab + Radiosurgery for Recurrent High-Grade Meningioma
NCT03604978Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in meningioma comparing Cohort A (nivolumab, radiosurgery) with Cohort B (nivolumab, ipilimumab, radiosurgery) (2 cohorts). Primary endpoints: Maximum Tolerated Dose up to 100 days, Adverse Events up to 100 days and 2 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03604978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604978.